eISSN 2508-3589
pISSN 2508-1926

Fig. 1.

Download original image
Fig. 1.

Mean change in best-corrected visual acuity (BCVA) from baseline during the follow-up period. BCVA improved significantly from baseline in the bevacizumab group at 1, 2, and 5 months, and at 1, 2, 5, and 6 months in the dexamethasone group. There were no significant differences between groups at each visit.

J Retin 2019;4:84-92 https://doi.org/10.21561/jor.2019.4.2.84
© 2019 J Retin